<DOC>
	<DOC>NCT01752699</DOC>
	<brief_summary>Neuropathic pain is a common condition and affecting 40 to 70% of the general population. Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment. Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line treatment for post-herpetic neuralgia (PHN) and had indication for the association of an opioid agent to their current drug regimen.</brief_summary>
	<brief_title>Methadone in Post-Herpetic Neuralgia Pain</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Patients with chronic (&gt;6 months) symptomatic PHN with visual analogical scale &gt;40/100mm use of first and second line drugs (tricyclic antidepressants, venlafaxine and gabapentinoids) Don't full the criteria above</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>neuropathic pain,</keyword>
	<keyword>post-herpetic neuralgia,</keyword>
	<keyword>methadone,</keyword>
</DOC>